Literature DB >> 1765139

Type-1 inhibitor of plasminogen activators. Distinction between latent, activated and reactive centre-cleaved forms with thermal stability and monoclonal antibodies.

M Munch1, C Heegaard, P H Jensen, P A Andreasen.   

Abstract

Type-1 inhibitor of plasminogen activators (PAI-1) occurs in purified preparations in a latent form that can be activated with denaturants; in vivo, latency is prevented by binding to vitronectin. We have compared latent, denaturant-activated and reactive centre-cleaved human PAI-1 with respect to thermal stability and affinity to monoclonal antibodies. By both criteria, latent and cleaved PAI-1 are very similar or indistinguishable, and clearly different from active PAI-1. Our findings suggest that the conformations of latent and reactive centre-cleaved PAI-1 are similar and resemble the so-called relaxed (R) serpin conformation, while that of active PAI-1 is different and resembles the stressed (S) serpin conformation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1765139     DOI: 10.1016/0014-5793(91)81395-o

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  7 in total

1.  Probing serpin reactive-loop conformations by proteolytic cleavage.

Authors:  W S Chang; M R Wardell; D A Lomas; R W Carrell
Journal:  Biochem J       Date:  1996-03-01       Impact factor: 3.857

2.  The conversion of active to latent plasminogen activator inhibitor-1 is an energetically silent event.

Authors:  Christian Boudier; Ann Gils; Paul J Declerck; Joseph G Bieth
Journal:  Biophys J       Date:  2005-01-14       Impact factor: 4.033

3.  S-ovalbumin, an ovalbumin conformer with properties analogous to those of loop-inserted serpins.

Authors:  J A Huntington; P A Patston; P G Gettins
Journal:  Protein Sci       Date:  1995-04       Impact factor: 6.725

4.  Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.

Authors:  K W Rodenburg; L Kjoller; H H Petersen; P A Andreasen
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

5.  The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas.

Authors:  Birgitte Vrou Offersen; Boye Schnack Nielsen; Gunilla Høyer-Hansen; Fritz Rank; Stephen Hamilton-Dutoit; Jens Overgaard; Peter A Andreasen
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

6.  Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands.

Authors:  Katrine E Pedersen; Anja P Einholm; Anni Christensen; Lotte Schack; Troels Wind; John M Kenney; Peter A Andreasen
Journal:  Biochem J       Date:  2003-06-15       Impact factor: 3.857

7.  Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.

Authors:  A Knoop; P A Andreasen; J A Andersen; S Hansen; A V Laenkholm; A C Simonsen; J Andersen; J Overgaard; C Rose
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.